Catalytic site-directed γ-secretase complex inhibitors do not discriminate pharmacologically between notch S3 and β-APP cleavages

被引:60
作者
Lewis, HD
Revuelta, BIP
Nadin, A
Neduvelil, JG
Harrison, T
Pollack, SJ
Shearman, MS
机构
[1] Merck Sharp & Dohme Res Labs, Neurosci Res Ctr, Dept Biochem & Mol Biol, Harlow CM20 2QR, Essex, England
[2] Merck Sharp & Dohme Res Labs, Neurosci Res Ctr, Dept Med Chem, Harlow CM20 2QR, Essex, England
关键词
D O I
10.1021/bi034310g
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The generation of gamma-secretase inhibitors which block the release of beta-amyloid peptide (Abeta) has long been an attractive therapeutic avenue for treatment or prevention of Alzheimer's disease (AD). Such inhibitors would reduce levels of Abeta available for aggregation into toxic assemblies that lead to the plaque pathology found in affected brain tissue. Cumulative evidence suggests that the S3 cleavage of Notch is also dependent on presenilins (PS) and is carried out by the multimeric PS-containing gamma-secretase complex. It is therefore possible that Notch function could be affected by gamma-secretase inhibitors. To assess the relationship between the cleavage of these substrates in the same system, Western blot cleavage assays have been established using a human cell line stably expressing both the beta-amyloid precursor protein (beta-APP) and the truncated Notch1 receptor fragment NotchDeltaE. Thus, a direct correlation may be made, following inhibitor treatment, of the decrease in the levels of the cleavage products, Abeta peptide and the Notch intracellular domain (NICD), as well as the increase in stabilized levels of both substrates. This analysis has been performed with a range of selected gamma-secretase inhibitors from six distinct structural classes. Changes in all four species usually occur in concert and with remarkably good agreement. A significant cleavage window is not clearly apparent in any case. Thus, these Notch and beta-APP cleavages cannot be dissected apart easily since they show the same pharmacological profile of inhibition. Whether this translates into proportionally reduced Notch signaling in vivo, however, remains to be seen.
引用
收藏
页码:7580 / 7586
页数:7
相关论文
共 49 条
[1]   Pharmacological knock-down of the presenilin 1 heterodimer by a novel γ-secretase inhibitor -: Implications for presenilin biology [J].
Beher, D ;
Wrigley, JDJ ;
Nadin, A ;
Evin, G ;
Masters, CL ;
Harrison, T ;
Castro, JL ;
Shearman, MS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (48) :45394-45402
[2]   Identification and characterization of presenilin-independent Notch signaling [J].
Berechid, BE ;
Kitzmann, M ;
Foltz, DR ;
Roach, AH ;
Seiffert, D ;
Thompson, LA ;
Olson, RE ;
Bernstein, A ;
Donoviel, DB ;
Nye, JS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (10) :8154-8165
[3]   Notch1 inhibits neurite outgrowth in postmitotic primary neurons [J].
Berezovska, O ;
McLean, P ;
Knowles, R ;
Frosh, M ;
Lu, FM ;
Lux, SE ;
Hyman, BT .
NEUROSCIENCE, 1999, 93 (02) :433-439
[4]   Notch1 and amyloid precursor protein are competitive substrates for presenilin1-dependent γ-secretase cleavage [J].
Berezovska, O ;
Jack, C ;
Deng, A ;
Gastineau, N ;
Rebeck, GW ;
Hyman, BT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (32) :30018-30023
[5]   Presenilin-1 differentially facilitates endoproteolysis of the β-amyloid precursor protein and Notch [J].
Capell, A ;
Steiner, H ;
Romig, H ;
Keck, S ;
Baader, M ;
Grim, MG ;
Baumeister, R ;
Haass, C .
NATURE CELL BIOLOGY, 2000, 2 (04) :205-211
[6]   A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain [J].
De Strooper, B ;
Annaert, W ;
Cupers, P ;
Saftig, P ;
Craessaerts, K ;
Mumm, JS ;
Schroeter, EH ;
Schrijvers, V ;
Wolfe, MS ;
Ray, WJ ;
Goate, A ;
Kopan, R .
NATURE, 1999, 398 (6727) :518-522
[7]   Presenilin-dependent γ-secretase activity modulates thymocyte development [J].
Doerfler, P ;
Shearman, MS ;
Perlmutter, RM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (16) :9312-9317
[8]   Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain [J].
Dovey, HF ;
John, V ;
Anderson, JP ;
Chen, LZ ;
Andrieu, PD ;
Fang, LY ;
Freedman, SB ;
Folmer, B ;
Goldbach, E ;
Holsztynska, EJ ;
Hu, KL ;
Johnson-Wood, KL ;
Kennedy, SL ;
Kholedenko, D ;
Knops, JE ;
Latimer, LH ;
Lee, M ;
Liao, Z ;
Lieberburg, IM ;
Motter, RN ;
Mutter, LC ;
Nietz, J ;
Quinn, KP ;
Sacchi, KL ;
Seubert, PA ;
Shopp, GM ;
Thorsett, ED ;
Tung, JS ;
Wu, J ;
Yang, S ;
Yin, CT ;
Schenk, DB ;
May, PC ;
Altstiel, LD ;
Bender, MH ;
Boggs, LN ;
Britton, TC ;
Clemens, JC ;
Czilli, DL ;
Dieckman-McGinty, DK ;
Droste, JJ ;
Fuson, KS ;
Gitter, BD ;
Hyslop, PA ;
Johnstone, EM ;
Li, WY ;
Little, SP ;
Mabry, TE ;
Miller, FD ;
Ni, B .
JOURNAL OF NEUROCHEMISTRY, 2001, 76 (01) :173-181
[9]   Amyloid-lowering isocoumarins are not direct inhibitors of γ-secretase [J].
Esler, WP ;
Das, C ;
Campbell, WA ;
Kimberly, WT ;
Kornilova, AY ;
Diehl, TS ;
Ye, WJ ;
Ostaszewski, BL ;
Xia, WM ;
Selkoe, DJ ;
Wolfe, MS .
NATURE CELL BIOLOGY, 2002, 4 (05) :E110-E111
[10]   Activity-dependent isolation of the presenilin-γ-secretase complex reveals nicastrin and a γ substrate [J].
Esler, WP ;
Kimberly, WT ;
Ostaszewski, BL ;
Ye, WJ ;
Diehl, TS ;
Selkoe, DJ ;
Wolfe, MS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (05) :2720-2725